the Pure study reveals that only 50% of patients around the world receive a treatment of the cardiac risk prevention
-According to the PURE study (Prospective Urban Rural Epidemiological study), about 60% of the world’s population who suffers from heart disease and 50 per cent of those who suffered a stroke are not taking any type of medication to prevent the risk of heart
-PURE has also shown that there is a direct relationship between the proportion of people who do not receive treatment and income economics country thus, in developing countries is 80% of patients who do not receive treatment for secondary prevention
-experts have also highlighted the high percentage, 11% of patients who do not receive this treatment in rich countries surveyed
-PUREIt has been submitted within the framework of the European society of Cardiology Congress, has analysed cases of 154,000 persons in 17 countries in different economic income
-the section of hypertension of the Spanish society of Cardiology (SEC) has also presented work in Congress, by who has shown a favourable evolution in the control of hypertension in Spain
Madrid, 2011-September the PURE study, conducted by researchers at McMaster University of Canada and presented in the framework of the Congress of the European society of Cardiology (ESC), has revealed that there is a significant under-utilization of cardiovascular drugs around the world. Specifically, persons should receive treatment for prevention of cardiac risk globally is only 50% of them have access to these drugs.
The PURE study was conducted between January 2003 and December 2009 and analysed cases of 154,000 adult patients aged between 35 and 70 years who had a history of coronary heart disease or stroke (LCA). The study was intended to examine differences in measures of secondary prevention among countries of different economic income.
PURE showed that there was a noticeable difference between the percentage of people receiving treatment in the countries in developing and rich countries. Thus, in the high-income countries that did not receive a treatment were the 11.2% of the patients, compared with 45.1% of patients in upper middle-income countries, 69.3% of the patients in lower middle-income countries and 80.2 per cent of patients in low-income countries.
It is important to note that the Pure study does not include all countries, but that has been a selection of 17, which is why countries like Spain would not be represented in this study. Even so, studies such as this have us serve health authorities take note of the medical shortcomings that exist in the world, that all we need to improve access of this type of drugs to the entire population. Most of these drugs are generic and, therefore, cheap ”, emphasizes Dr. Alberto Cordero, Member of the SEC and the service of Cardiology, University Hospital of San Juan de Alicante.
On the explanation of the results, the researchers believe that it could be due to a set of factors, such as the limited availability of these drugs in the countries of low and middle-income, the difficulties in transportation or limited access to medical services.
Spanish relevant representation at the Congress of the world largest Cardiology
Spain has collaborated very actively at the XXVIII Edition of the Congress of the European society of Cardiology, that it has submitted 249 original works with more than 30,000 professionals who have gathered since last Saturday and until this afternoon in the French capital, city that hosts this year Edition of the reference Congress on cardiology.
One of the studies that have been presented during the Congress has been designed by the section of Arterial hypertension of the SEC and backed by the research agency of the SEC, which aims to analyse the evolution in the control of blood pressure in the last ten years in Spain.
The study has analyzed the records of 25,000 patients, and it has been shown that the prevalence of hypertension blood (HTA) current is 30%, reflecting an increase of 23% in the last ten years, both in cardiac patients and persons who do not suffer this type of ailments.
The study also revealed that the prevalence of hypertension in patients with heart failure present is 90%, increased 16.5 per cent in the last decade. Patients suffering from coronary heart disease also suffer from hypertension is 86% (increase of 30.1% in the last ten years), while the percentage of patients with atrial fibrillation who are suffering from hypertension is 88%, an increase of 33.2%.
Control of pressure has also increased by 26.5%, ten years ago it was 40% while is now 55% in the population in general and in patients with established disease, the increase has been 60% (from 20% to 32%).
These results are important because they demonstrate that although each time there are more people suffering from high blood pressure, it is also becoming increasingly higher preventive awareness of this important cardiovascular risk factor. Not in vain, hypertension is present in seven out of every ten patients cardiovascular ”, concludes Dr. Lamb.
Other studies that have been tabled in the framework of the Congress has been carried out by the University Hospital complex of Santiago and it has been to analyse the relationship between soluble receptor for advanced glycation (RAGE) compounds and acute coronary syndrome. Through this study found that the presence of a large amount of soluble in blood RAGE is a forecast of the bad hospital the patient’s evolution after having suffered an acute coronary syndrome.
Advanced glycation products are circulating molecules in the blood that reflected largely the oxidative stress that the Agency, mediating its effects through these receptors (RAGE) is subject. High concentrations of such products are harmful to our bodies, to be regarded as potential inducers of diseases such as Alzheimer’s disease, atherosclerosis, and old age-related degenerative disorders, as well as micro complications and macrovascular of diabetes mellitus.
Through this study we can detect in the future which patients are at high risk in the forecast of the evolution of the hospital after suffering an acute coronary syndrome. This is the first study that relates the RAGE with acute coronary syndrome and we hope that eventually it can be a bookmark commonly used by cardiologists ”, emphasizes Dr. Sergio Raposeiras, Member of the SEC and the University Hospital complex of Santiago cardiologist. In the hospital are working to better understand the evolution and prognosis of coronary syndrome acute, so we are creating a database coordinated by the Abu-Assi Emad Dr. collects all revenue by this disease and we hope to help us deal better with this type of patients ”.
Spanish society of Cardiology (SEC)
The Spanish society of Cardiology (SEC) is a scientific and professional organization non-profit dedicated to increasing the State of knowledge about the heart and the circulatory system, to make progress in the prevention and treatment of their diseases and to improve survival and quality of life for heart patients.
The SEC has among its principal objectives contribute to research international, especially European and Latin American, create national and international links for the development of actions and represent all interested professionals in the field of cardiology.
